PharVision Advisers’s CRH CRH Stock Holding History

PharVision Advisers’s Portfolio CRH Stock Details CRH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,280	Closed	-$285K	–	231
2025 Q4	$285K	Buy	+2,280	New	+$272K	0.14%	303
2025 Q1	–	Sell	-4,667	Closed	-$432K	–	319
2024 Q4	$432K	Buy	+4,667	New	+$449K	0.37%	66

Other funds holding CRH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

PharVision Advisers's CRH Position: Q1 2026 in Review

PharVision Advisers sold out of CRH (CRH) in Q1 2026, closing a stake of 2,280 shares — an estimated $285K sold.

PharVision Advisers first reported a position in CRH in Q4 2024 and held it in 2 quarters. The position peaked at $432K in Q4 2024. 1,006 funds tracked by Wall St. Rank hold CRH as of Q1 2026.

PharVision Advisers reported no remaining CRH position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 2,280 CRH shares in Q1 2026, an estimated $285K.
PharVision Advisers first reported a position in CRH in Q4 2024 and held it in 2 quarters.
PharVision Advisers's CRH position peaked at $432K in Q4 2024.
1,006 funds tracked by Wall St. Rank held CRH as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.